Abiopharma

🔍 Goncalves Joana (Executive)

Company: Oruka Therapeutics, Inc. (ORKA)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Acquired 3,500 shares of Common Stock at $6.84 per share (Direct)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 37,165.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 3,500 shares of Common Stock at $7.8 per share (Direct)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 40,665.00 | transaction_form_type: 4
• Sold 1,636 shares of Common Stock at $68.3839 per share (Direct)
  Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 39,029.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 5,064 shares of Common Stock at $69.4209 per share (Direct)
  Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 33,965.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 300 shares of Common Stock at $70.6233 per share (Direct)
  Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 33,665.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 947 shares of Common Stock at $69.69 per share (Direct)
  Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 32,718.00 | transaction_form_type: 4 | Footnotes: F6
• Sold 3,500 shares of Employee Stock Option (right to buy) at $6.84 per share (Derivative)
  Date: 2026-06-15 | Code: M | Expires: 2034-05-06 | equity_swap_involved: 0 | shares_owned_after: 204,063.00 | transaction_form_type: 4 | Footnotes: F7
• Sold 3,500 shares of Employee Warrant (right to buy) at $7.8 per share (Derivative)
  Date: 2026-06-15 | Code: M | Expires: 2034-07-14 | equity_swap_involved: 0 | shares_owned_after: 175,492.00 | transaction_form_type: 4 | Footnotes: F8

Footnotes:

• F1: Includes 288 shares acquired under the Oruka Therapeutics, Inc. stock purchase plan on June 8, 2026.
• F2: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.97 to $68.96, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.98 to $69.83, inclusive.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.79, inclusive.
• F6: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.
• F7: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
• F8: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.